Predicting the functional impact on the performance of daily activities in people with PD: a novel approach based on objective measures obtained by inertial sensors
Objective: To predict global motor disabilities using symptomatology assessed with inertial sensors, medication regimen, and cognitive deficits through: (1) a clustering method on performance metrics…Substantia Nigra (SN) Hyperechogenicity as seen in Transcranial Sonography (TCS) is a reliable disease progression marker from Stage I to Stage II in Early Onset Parkinson’s Disease (EOPD)
Objective: To test the hypothesis that SN hyperechogenicity seen in transcranial sonography (TCS) can be used as a reliable disease progression marker from stage I…Speech impairment as a marker of clinical changes in premanifest Huntington’s disease
Objective: Speech disturbances have been described in premanifest Huntington’s Disease (HD). Yet a recent systematic review and meta-analysis highlighted disagreement in the literature regarding the…Assessment of Gait in Huntington’s disease patients using EncephaLog smartphone’s application
Objective: Huntington’s disease (HD) patients cope with unique gait disturbances. Proper evaluation of gait in these patients is highly needed. Dyskinesia may negatively affect validity…Impact of caring for patients with Huntington’s disease on work status
Objective: To describe changes in the employment status of family members caring for a person with Huntington’s disease (HD) in the US and Europe. Background:…Involuntary movements with abnormal brain imaging: A Case Report
Objective: To present a case of juvenile-onset Huntington's disease (HD) with a mixed phenotype and abnormal brain imaging. Background: HD is an autosomal-dominant neurodegenerative disorder…Effects of Cognitively Challenging Agility Exercise Program on Clinical and Objective Measures in People with Parkinson’s Disease
Objective: To investigate the effects of a 6-week cognitively challenging exercise intervention in people with Parkinson’s disease (PD). Background: Gait and balance impairments have been…Safety and Tolerability in Parkinson’s Disease Patients Treated with a Continuous Subcutaneous Infusion of ABBV-951: Design of a 52-Week Phase 3 Study
Objective: To assess the local and systemic safety and tolerability of ABBV-951 delivered as a continuous subcutaneous infusion (CSCI) for 24 hours daily for up…Open-label safety and tolerability of L-Dihydroxyphenylserine (L-DOPS) and high dose carbidopa therapy in Parkinson’s disease patients
Objective: To assess safety, tolerability, and central effects of L-Dihydroxyphenylserine (L-DOPS), in Parkinson’s disease (PD) patients treated with DOPA decarboxylase inhibition. Background: Norepinephrine (NE) is…Development Of Anti-Parkinsonism Poly Herbal Sustained Release Formulation Composed Of Potential Traditional Plant Extracts
Objective: Parkinsonism is one of the commonest neurodegenerative diseases, which is characterized by a selective and progressive degeneration of dopaminergic neurons, causing a series of…
- « Previous Page
- 1
- …
- 87
- 88
- 89
- 90
- 91
- …
- 217
- Next Page »